Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Carcinoma, Non-Small-Cell Lung

Carcinoma

Lung Neoplasms

Lung Diseases

Thoracic Neoplasms

Bronchial Neoplasms

Carcinoma, Bronchogenic

Respiratory Tract Neoplasms

Respiratory Tract Diseases

Recombinant human Apo-2 ligand for Injection

Mimetic agent for recombinant human Apo-2 ligand for injection

150μg/kg/d IV (in the vein), on day 1 to 7 of each 21 day cycle

Placebo

Yuankai Shi, Ph.D.

The trial is to evaluate the efficacy and safety of recombinant human Apo-2 ligand in treating patients with advanced retreated non-small cell lung cancer

A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection

A Randomized, Double-blind, Placebo-controlled in Parallel, Multicenter Phase III Trial of Recombinant Human Apo-2 Ligand for Injection（Dulanermin for Injection）in the Treatment of Advanced Non-small Cell Lung Cancer

Survival information may be obtained via telephone contact with the patient, patients family or by checking the patients notes, hospital records, contacting the patients general practitioner or public death registry, where it is possible to do so under applicable local laws.

Progression Free Survival (PFS) : the time from start of study treatment to the first documentation of objective disease progression (PD) or death from any cause.

Objective response rate: the percentage of subjects who have at least one visit response of CR or PR prior to any evidence of progression

Disease control rate: the percentage of subjects who have at least one visit response of CR or PR or SD prior to any evidence of progression.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection	NCT03083743	Non-small-cell ...	Recombinant hum... Placebo	18 Years - 75 Years	Shanghai Gebaide Biotechnology Co., Ltd.
A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection	NCT03083743	Non-small-cell ...	Recombinant hum... Placebo	18 Years - 75 Years	Shanghai Gebaide Biotechnology Co., Ltd.

Spots Global Cancer Trial Database for antineoplastic agents, cytokines